Triagem primária de doadores de sangue por teste de ácidos nucléicos: desenvolvimento de um método não-comercial e resultados by Wendel, Silvano et al.
Rev. Inst. Med. trop. S. Paulo
49(3):177-185, May-June, 2007
(1) Banco de Sangue, Hospital Sírio Libanês, São Paulo, SP, Brasil.
(2) Centro de Imunologia e Imunogenética, São Paulo, SP, Brasil.
(3) Banco de Sangue, Hospital Nove de Julho, São Paulo, SP, Brasil.
(4) Banco de Sangue, Hospital Oswaldo Cruz, São Paulo, SP, Brasil.
(5) Banco de Sangue, Hospital Evaldo Foz, São Paulo, SP, Brasil.
(6) Departamento de Microbiologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brasil.
Correspondence to: Silvano Wendel, Rua Peixoto Gomide 515, 12º andar, 01409-001 São Paulo, SP, Brasil, Fax + 55 11 3284 5315, Phone + 55 11 3285 5999. E-mail snwendel@uninet.com.br
PRIMARY SCREENING OF BLOOD DONORS BY NAT TESTING FOR HCV-RNA: DEVELOPMENT OF
AN “IN-HOUSE” METHOD AND RESULTS
Silvano WENDEL(1,2), José Eduardo LEVI(1,2), Deise Tihe TAKAOKA(2), Isabela Cristina SILVA(2), Juliana Polachini de CASTRO(2), Mário A. TOREZAN-FILHO(1,2),
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SUMMARY
An “in-house” RT-PCR method was developed that allows the simultaneous detection of the RNA of the Hepatitis C Virus
(HCV) and an artificial RNA employed as an external control. Samples were analyzed in pools of 6-12 donations, each donation
included in two pools, one horizontal and one vertical, permitting the immediate identification of a reactive donation, obviating
the need for pool dismembering. The whole process took 6-8 hours per day and results were issued in parallel to serology. The
method was shown to detect all six HCV genotypes and a sensitivity of 500 IU/mL was achieved (95% hit rate). Until July 2005,
139,678 donations were tested and 315 (0.23%) were found reactive for HCV-RNA. Except for five false-positives, all 310 presented
the corresponding antibody as well, so the yield of NAT-only donations was zero, presenting a specificity of 99.83%. Detection of
a window period donation, in the population studied, will probably demand testing of a larger number of donations. International
experience is showing a rate of 1:200,000 - 1:500,000 of isolated HCV-RNA reactive donations.
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INTRODUCTION
Despite the excellent laboratorial tests in place today for blood
screening, transmission of biological agents still occur as seen in the
near past with the Hepatitis C Virus (HCV)1 and the Human
Immunodeficiency Virus (HIV)22 and more recently in human
encephalitis cases caused by West Nile Virus (WNV) transmitted by
blood products and solid organ transplantation28.
In order to avoid transfusion of infectious units, blood banks rely
primarily on clinical and epidemiological screening of blood donors,
and secondly, on testing of their blood for markers of transmissible
agents. The detection of antibodies and/or antigenic portions of these
agents is the standard approach in blood screening. However, both
suffer from inherent deficiencies: antibody tests may allow an infected
unit to go undetected during the serological window period, the time
span between infection and the development, by the potential donor,
of detectable antibodies. Antigen detection may lead to false-negative
results due to genetic variability of the microorganism, as illustrated
by an p24 antigen escape mutant9, and, in practice, a diminished
sensitivity of HIV p24 antigen and HCV core antigen in comparison to
NAT has been observed7,34,36.
Molecular methods targeting fungi, bacteria and viruses nucleic
acids have been introduced in the clinical pathology setting in the 1990s,
driven in part by the successful clinical use of two quantitative viral
load systems (HCV and HIV viral load testing, Amplicor™ Roche).
The development of a tool able to reduce significantly the window
period and providing a high-degree of specificity became the goal for
all partners involved on the blood circuit12.
By 1997, the German Red Cross had already developed and
implemented an ‘in-house” PCR based test for this purpose29, soon
followed by Japan14 and Scotland4. In parallel we were able to introduce
nucleic acid testing (NAT) for the hepatitis C virus (HCV) RNA in
March 199837.
NAT introduction in any country has to take in consideration the
particularities of its blood system. The pool size, if done on donation
pools, and the time taken for resolution of reactive primary pools is
directly related to the availability of the blood supply. Other factors
like the prevalence of reactive donors and financial resources are also
important issues.
Our planning was based on two premises:
- NAT and serology should be processed in parallel, meaning that
we wouldn’t remove antibody-reactive samples from pools,
providing a routine challenge and quality control of the “in-house”
NAT method.
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- Before introduction in routine, NAT might prove to be feasible
and reliable, with a detection limit of at least 5000 IU/mL of the
donor’s serum, and able to detect all major HCV genotypes.
We decided to build-up a system of bi-dimensional pooling that
would allow simultaneous processing of many samples and, when
positive, it wouldn’t result in the blockage of all individual sera
contained in the pool. To our knowledge, this kind of pooling is not
adopted on primary screening in any center elsewhere. The USA has
been using single pools of 16-24 samples34 while Japan24 and Germany30
adopted pools of 48-96 donations.
The purpose of this publication is to describe the validation of a
NAT method in place at our laboratory since 1998 and to report the
results obtained up to July 2005.
MATERIAL AND METHODS
a) Donors and donations: Voluntary blood donors gave written
informed consent for participation in this ongoing study. For this
purpose a Serum Separation Tube (SST II, Becton-Dickinson, São
Paulo, Brazil) was drawn right after collection of the blood bag. Tubes
were centrifuged according to manufacturer instructions and transported
to the molecular biology lab on the same day. Some donations were
eventually kept refrigerated and transported at 4 - 8 oC to the molecular
biology lab on the following day. All donations were tested in parallel
at the serology lab for the mandatory screening tests (anti-HCV, anti-
HTLV-I/II, anti-HBc and HBsAg, anti-HIV 1 and 2, Chagas, Syphilis,
and abnormal hemoglobin detection). Donations were collected
between March 1st 1998 and July 31st 2005 at blood banks in São Paulo
city (Hospital Sírio Libanês, Hospital Nove de Julho, Hospital Oswaldo
Cruz, Hospital Evaldo Foz), Bragança Paulista (Núcleo de Hemoterapia
de Bragança Paulista, São Paulo State) and Brasília (Hemolago, Federal
District). More than 95% of the donors lived in São Paulo city at the
time of donation. Frequency of reactivity to routine serological markers
are shown on Table 1 below, as a general characterization of the enrolled
donor population.
This study was approved by the ethical committee from the Instituto
de Ciências Biomédicas, Microbiology Department from the University
of São Paulo, São Paulo, Brazil.
b) Pooling: Pooling was performed on an automated device (Hamilton
Microlab AT, Reno, NV, USA) by pipetting donor’s serum to RNAse/
DNAse free molecular biology grade microwell plates (NUNC, Roskilde,
Denmark). Samples were grouped twice bidimensionally (“chessboard”
format) on “minipools” of 6-12 donations (hereby generically
denominated “pools”), in accordance to the daily number of samples to
be tested, each donation contributing with 20.8 - 41.6 µL of serum, to a
total of 250 µL. For example, if a pool of six samples was built, each
donation contributed with 50 µL to a total of 300 µL. After
homogenization, 250 µL was taken for the extraction process. If a pool
of twelve was built, each donation contributed with 30 µL, and 250 µL
removed from the 360 µL initially pooled. Every sample was represented
on two “pools” and positioned in a way that allowed readily identification
of a positive or inhibitory sample, obviating the need for dismembering
reactive “pools”. Pools were made both in the horizontal and vertical
axis. Each homogenized pool was manually transferred to a conventional
microtube. A scheme of pooling is depicted on Figure 1.
c) NAT METHOD:
c1) RNA extraction: RNA was extracted from 250 µL of serum pools
with 750 µL of Trizol LS® (Invitrogen, São Paulo, Brazil), in the
presence of 20 µg of glycogen as a carrier and 20,000 copies of an
external control (EC) synthetic RNA (pAW 109 RNA, Applied
Biosystems, Brazil).
c2) Reverse Transcription (RT): Total RNA was resuspended in 18
µL of Reverse Transcription mixture containing RNAse Inhibitor 1 U/
µL (Invitrogen, São Paulo, Brazil), DTT 1 mM, 1x PCR buffer (10
mM Tris-HCl pH 8.3; 50 mM KCl; 1.5 mM MgCl2) 200 µM dNTPs,
3.5 mM MgCl2, and incubated for five minutes at 65 oC , then
centrifuged at 3,000Xg, 4 oC for one minute. Moloney Murine Leukemia
Table 1
Serological markers prevalence& on this study blood donor population (n = 139,678 donations)
Marker HBsAg Anti-HBc Anti-HCV Anti-HIV1/2 p24 Ag# Anti-HTLV I/II Syphilis Chagas ALT > 84 U/L*
Prevalence (%) 0.58 3.41 0.58 0.35 0.07 0.25 0.67 0.74 0.89
&
 Samples repeatedly reactive for the screening assay. * This marker is no longer mandatory and was discontinued in 2004. n = 126,180 donations. # Replaced by HIV
NAT since July 2001. n = 62,123 donations.
Fig. 1 - Scheme of the pipetting tray for pooling. Each circle corresponds to one donation.
Horizontal (12 pools, 1-12) and vertical pools (8 pools, 13-20) are identified by Arabic
successive numbers. A hypothetic NAT reactive donation is represented by a dark circle,
which corresponds to pools 2 and 15, which would allow only one sample to be simultaneously
present in both pools, rendering an automatic identification of the putative positive sample.
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Virus Reverse Transcriptase (M-MLV RT, Invitrogen, São Paulo, Brazil)
2.5 U/µL and random hexamers 2.5 µM (Invitrogen, São Paulo, Brazil)
as primers, were added to the mixture and subsequently incubated for
10 minutes at room temperature, then 30 minutes at 37 oC and finally
boiled for five minutes.
c3) HCV and external control primer choice: cDNA was synthesized
from samples obtained from patients chronically infected by HCV and
requiring HCV viral load testing for treatment monitoring. Samples were
diluted with negative plasma in order to obtain viral loads of 50, 500,
5,000 and 50,000 copies/mL. These samples were processed as described
above and submitted to amplification with four primer pair combinations,
HC11/HC1831; SM3/HC18 (SM3 is a new sense primer here described);
P32/P36 and P33/P48, these last two in a nested-PCR format where
P32/P36 PCR product is used as a template for P33/P48 amplification,
as described26. Primers sequences are given in Table 2 below.
c4) Amplification (1st generation method): This method was
introduced in March 1st 1998 as a routine screening test for HCV-RNA
and was replaced by a multiplex PCR mixture (item c5 below) in July
1st 2001, when HIV-RNA testing became a routine.
One fourth of the total cDNA (5 µL) corresponding to 5.2 - 10.4 µL
of each donor serum, was directly applied on a 25 µL (final volume)
Polymerase Chain Reaction (PCR) solution, containing 3.5 mM of MgCl2,
200 µM of dNTPs, 1.25 Units of Taq Polymerase (Pharmacia, Uppsala,
Sweden), 500 nM of a primer pair (sense SM3 + antisense HC 18)
spanning a fragment of 268 bp from the HCV 5’ untranslated region
(nucleotide - 267 to -1) and a primer pair (sense DM 151 + antisense
DM 152) spanning 308 bp from the external control cDNA. Forty cycles
of 94 oC 30 seconds, 55 oC 30 seconds and 72 oC one minute were preceded
by a 95 oC five minutes incubation and followed by a final step of seven
minutes at 72 oC on a Perkin-Elmer 9600 Thermocycler.
c5) Amplification (2nd generation method): Multiplex PCR – 10 µL of
cDNA was added to a PCR mixture containing three primers pairs (HCV,
HIV21 and External Control), glycerol 5%, cresol red 0.25 µg/µL, dNTPs
0.2 mM (A,C,G,U), 1.25 U of Platinum Taq (Invitrogen, São Paulo, Brazil),
0.03 U of Uracyl-N-Glycosilase (UNG, Amersham, São Paulo, Brazil) in
a final volume of 25 µL. This mixture was submitted to the following
thermocycling parameters: 95 oC for five minutes then 40 cycles of 94 oC
/30 seconds; 55 oC /30 seconds; 65 oC / 1 minute, and a final incubation
step at 65 oC for seven minutes. The method was validated and performed
on the following thermocyclers: Applied Biosystems models 2400, 9600
and 9700 and MJ Research model PTC-100.
c6) Electrophoresis: PCR products from the External Control (308
bp) and the HCV 5’untranslated region (268 bp) were run at 200mV/
100mA for one hour on an ethidium bromide stained 3% agarose gel
and directly observed under UV light on an UV Imager (Ultra-Violet
Products, Cambridge, UK). All images were digitalized and stored
allowing the traceability of the results. A legend was engraved on the
gel image and a photo printed in a thermal printer, accompanying the
daily working sheet.
c7) Controls: On each run four controls were included from the
extraction; triplicates of a mix of HCV and HIV reconstituted
international standards (available from WHO, National Institute for
Biological Standards and Controls, Potters Bar, Herts, UK, HCV-RNA
International Standard Cat. # 96/798 and HIV-RNA International
Standard Cat. # 97/656 I) containing 500 IU/mL of both HCV and
HIV-RNAs and one seronegative and NAT negative plasma. During
the HCV-only screening phase, controls containing exclusively HCV
were employed. An amplification control was included at the PCR
step consisting of a “pool” of cDNAs from standards, previously shown
to correctly amplify HCV and HIV. It was required two out of three
replicates to amplify HCV and HIV RNA to validate the entire run. A
negative result for HCV and HIV RNA on the negative control was
mandatory; otherwise the run was invalid and repeated. The previously
obtained cDNA “pool” from standards served to guide us in case of a
run failure, i.e. if the run is completely negative but this amplification
control was correct we started again from extraction; if this control
failed we started from the PCR step onwards.
d) Validation of NAT: This method was validated for routine use by:
d1) Testing HCV quantitated plasma samples from donors and
patients: Forty-two samples quantified by the referred HCV viral load
test were tested neat and diluted to the depicted concentrations. At that
time HCV viral load test adopted the copies/mL unit so sensitivity
was estimated based on this. Results are shown on Table 3 below.
Table 2
Primers from the HCV 5’UTR tested during NAT standardization
Primer Sequence 5’→3’





SM 3 (sense) CTAGCCATGGCGTTAGTA
HC 18 (antisense) GGTGCACGGTCTACGAGACCT
HC 11(sense) GGCGACACTCCACCATAGATCACT
pAW 109 RNA primers (External Control)
DM 151 (sense) GTCTCTGAATCAGAAATCCTTCTATC
DM 152 (antisense) CATGTCAAATTTCACTGCTTCATCC
Table 3
Sensitivity estimation of the test (1st generation) challenged against 42 samples
from chronic hepatitis C patients, diluted to the indicated viral load








* For two samples there was not enough material to perform the dilution series
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d2) Sensitivity: Lyophilized WHO standards, purchased from the NIBSC,
were reconstituted in RNAse free-ddH2O and diluted with negative
plasma to the desired concentrations. Twenty replicates were run three
times at five dilution points namely 1,000 IU/mL; 500 IU/mL; 250 IU/
mL; 50 IU/mL and 10 IU/mL of HCV-RNA. The detection limit of the
method was 500 IU/mL of HCV-RNA (95% hit rate, Table 4).
d3) Specificity: On testing of 1,000 seronegative donations there was
no sample assigned as “initially reactive”. In quality control blind
panels, no negative sample was assigned as reactive.
d4) Reproducibility: Assessed by running in parallel to serological
routine for two months and by the performance of three distinct
operators. The method was shown to be robust and reproducible,
independent of operator, provided that the technician was properly
trained.
d5) Genotypic coverage: HCV RNA Genotype Reference Panel for
NAT (NISBC code 02/202) was purchased from NISBC. HCV Panel
contains genotypes 1-6. All samples were detected by the method both
individually (Fig. 2) and in pools.
d6) External Assessment: Yearly participation on blind panels prepared
for quality control on NAT labs (Viral Quality Control Program VQC,
organized by CLB, Amsterdam, Netherlands). All samples containing
more than 500 IU/mL of HCV-RNA were correctly assigned as reactive.
No false-positives were observed.
e) Re-validation of NAT when switching from 1st to 2nd generation:
All procedures above were repeated with identical results. Sensitivity
was neither reduced nor improved, and specificity was superior to
99.9%, as before. Main modifications were: increase in the cDNA input
from 5 µL to 10 µL; replacement of a conventional enzyme Taq
Polymerase by an enzyme providing higher processivity and “hot-start”
namely Platinum Taq (Invitrogen, São Paulo, Brazil); addition of
glycerol and cresol red; adoption of an enzymatic control of
contamination provided by amplification in the presence of dUTP
instead of dTTP and addition of UNG21.
f) Confirmatory NAT assay: Repeatedly reactive samples were
submitted to an alternative NAT test, either on the same sample or
from a new one collected from the putative positive donor. HCV
confirmatory test consisted of a nested-PCR targeting also the 5´ UTR,
but with primers positioned in HCV genome in a way to avoid
contamination from potential NAT-screening amplicon carryover. Five
µL of the cDNA, produced as above, were included on a 25 µL final
volume PCR, containing primers P32/P36. Five µL of this first-round
PCR was transferred to a second tube containing primers P33/P48, as
described26. Universal anti-contamination precautions were rigorously
observed. Detection limit of this assay is 100 IU/mL (99% hit rate).
g) HCV genotyping: Genotyping of 33 unselected HCV positive donors
was done by amplification of 310 base pairs from the 5’-Untranslated
Region (5’UTR)31. PCR products were purified by filtration on a
microspin column device (Microcon-30, Amicon Inc., USA) and
quantified on gel electrophoresis by comparison to standards employing
the GelWorks software (Ultra-Violet Products, UK). Cycle sequencing
with the same PCR primers was performed with a dye-terminator DNA
sequencing kit (Applied Biosystems, USA) and fragments were run
on an automated DNA sequencing apparatus (ABI Prism 377 DNA
Sequencer, Applied Biosystems, USA). Assignment of the genotype
was based on type-specific motifs present on the 5’UTR33.
h) HCV-RNA viral load: HCV-RNA quantification was performed by
use of the ROCHE HCV-Monitor v 1.0 kit, according to the
manufacturer instructions. Upper limit of this method is 500,000 copies/
mL.
i) HGV-RNA PCR: HGV-RNA was detected by amplifying a sequence
from the 5’UTR in a single-step assay and also by a nested-PCR method
targeting the NS3 region, as described20.
j) EIA: Anti-HCV testing (EIA) was performed either with ABBOTT,
Axsym HCV 3.0 (Wiesbaden - Delkenheim, Germany) or ORTHO Anti-
HCV EIA 3.0 (Raritan, New Jersey, USA) according to manufacturer’s
instructions. These solid phase enzyme immunoassays contain peptides
and recombinant proteins attached, representing the core and non-
structural proteins NS3, NS4 and NS5. An absorbance/cut-off (A/CO)
ratio > 1 is considered reactive, according to the manufacturer
criteria.
Table 4
Sensitivity estimation of the test (1st generation) when challenged against a
quantified International Standard
HCV-RNA International Reactive samples/







MW = molecular weight marker, 100bp ladder (Invitrogen, São Paulo, Brazil). 1- 6 indicates the corresponding
genotype sample; Pl = Negative human plasma (control); C+ = duplicate of cDNAs from HCV and HIV
international standards; No = no DNA control, H2Odd was added to the PCR mix; EC = External control.
Fig. 2 - HCV-RNA Genotype Panel from NISBC comprising genotypes 1-6 (viral load not
available) was submitted to the NAT assay.
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k) Immunoblot (IB): Samples repeatedly reactive to screening EIA,
independent of NAT results, underwent a confirmatory step, using
LiaTek HCV III (Innogenetics, Zwijndrecht, Belgium). Test strips are
coated with synthetic recombinant HCV antigens from the E2/NS1,
NS3, NS4, NS5 and core proteins. Binding of serum/plasma antibodies
to one or more antigen lines results in color development and are
interpreted as a reactive sample, according to manufacturer’s
instructions.
l) ALT levels: ALT level determination was systematically performed
in an Alcyon 300/300i analyzer by a UV-kinetic method (Abbot Park,
IL, USA), as an additional screening test until its discontinuation in
2004. Samples presenting values higher than 84 U/L were rejected,
according to internal operational procedures.
RESULTS
a) Primer choice: Among the primer combinations tested, SM3/HC18
displayed the greatest sensitivity on single-step assays. Samples
containing 500 copies/mL were readily detected by this system as well
as by the second-round of the nested PCR (Fig. 3). At higher HCV-RNA
concentrations, signals were similar for all combinations19. This analysis
led to the choice of primer pair SM3/HC18 for our “in-house” NAT test.
b) Blood donors screening: The NAT method has been in use as a
routine since March 1998 for HCV RNA and in July 2001 HIV RNA
screening was added to the test, in a multiplex format (Fig. 4), replacing
p24 Ag detection21. Until July 2005 139,678 donations were tested for
HCV RNA, including 77,555 also tested for HIV RNA. 48,272 PCR
reactions were performed, counting pools and controls. 550 samples
were NAT initially reactive (0.39%) demanding their testing individually
in duplicate on the next day routine. If they were found repeatedly reactive
the donation was rejected and discarded, otherwise (non-reactive) it was
released for transfusion. 1,114 samples were blocked for inadequacy
(0.80%; external control non-reactive) demanding their inclusion in pools
on the next day routine. Only one sample was repeatedly inadequate,
both in pools and individually (Table 5). This donor was advised to wait
for six months and then to donate again, which resulted in a negative
result, therefore, acceptable for transfusion and he was subsequently
reintegrated. By serology, 805/139,678 donations (0.58%) were rejected
due to repeatedly reactive results while NAT rejected 315/139,678
(0.23%), where 310 (98.4%) were also reactive by the NAT confirmatory
method using nested-PCR (Table 5).
In practice, the observed specificity of the method was 99.83% when
considering initially reactive donations, derived from the 235 samples
that were initially reactive but didn’t confirm either when analyzed by
the screening NAT test individually (230) or when submitted to the
ancillary NAT confirmatory test (five samples), the nested-PCR described
in item “f” of material and methods section. However, if evaluating
rejection due to the initially reactive (pools)/ repeatedly reactive
(individual sample) analysis, the specificity is > 99.9% since only five
samples displayed this pattern and were further non reactive in the
confirmatory assay. These five NAT false-positives amplicons were
sequenced, revealing the presence of an HGV “Iowan” strain38 in four of
them. Those four were also reactive for two distinct HGV-specific
molecular assays, confirming their status of HGV carriers. The other
NAT false-positive result was attributed to amplicon contamination of
the index sample and/or the corresponding cDNA. Approximately 17%
of the blot-reactive samples were NAT non-reactive (Table 6).
A - HC11/1831, B - SM3/HC18 (this study), C - P32/P36 and D - P33/P4826. The product of C was used as
a first-round product for D set (“nested”-PCR). 1-5 are HCV-RNA positive samples quantified by the Roche
HCV-Monitor method and diluted to 500 copies mL-1. Primer pair B shows sensitivity similar to the nested
products (D).
Fig. 3 - Comparison of amplification efficiency of four different 5’UTR primer pairs for
HCV-RNA RT-PCR.
Table 5
Overall NAT HCV-RNA/EIA screening results. n = 139,678 donations
Test result % n
Initially reactive (NAT HCV-RNA) 0.39% 550
Repeatedly reactive HCV-RNA 0.23% 315@
Repeatedly reactive (EIA) anti-HCV 0.58% 805
NAT- inadequate (initially inadequate) 0.80% 1114
NAT- repeatedly inadequate 0.001% 1
Confirmed reactive HCV-RNA/ EIA Neg. 0 0
@
 Includes five samples that were non-reactive in the NAT confirmatory nested-
PCR test. Corresponding amplicons were sequenced and four identified as HGV.
They were considered “cross-reactions” attributed to sequence homology between
HCV and HGV. One of them was also EIA HCV reactive/Blot indeterminate.
Table 6
HCV-RNA/EIA and Immunoblot results on samples repeatedly reactive for
anti-HCV (EIA, n = 805)
Test result n %
Rejected for Anti-HCV 805 0.58
BLOT reactive 268 33.29*
BLOT non-reactive 229 28.45*
BLOT indeterminate 147 18.26*
BLOT not done 161 20.00*
BLOT indeterminate/NAT reactive 4 2.72&
BLOT reactive/NAT non-reactive 46 17.16#
*Percentage from the total number of samples submitted to blot (repeatedly reactive
for anti-HCV); & Of all blot indeterminate samples; # Of all blot reactive samples.
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c) Genotypes and viral load: Genotypes detected among donors were
1a (13/33), 1b (11/33), 2b (1/33) and 3a (8/33). Observed viral load
was generally very high (median = 500,000 copies/mL).
d) ALT levels and EIA A/CO rate in viremic (NAT RT) and non-
viremic (NAT NRT) donors: Mean ALT values were calculated for
donors serologically confirmed for HCV (blot RT) grouped according
to NAT reactivity. Viremic donors displayed mean ALT values above
the cut-off for this marker (84 U/mL), but the median for this group
was only 54 U/mL, as seen in Table 7A. Accordingly, the mean A/CO




This study describes our experience with HCV NAT testing by an
“in-house” developed method for screening of blood donors.
Development of our own methodology, which in 1997 was the unique
option for those willing to NAT screen their blood supply, took us 18
months of research that culminated in the process described above.
We were among the first blood banks to report NAT data in the
literature18, however, at this time, due to the small number of samples
analyzed, these results had low impact, in comparison to those obtained
by large centralized blood banks processing hundreds of thousands
donations per year. It became evident to us, that every blood bank
must adapt their NAT process to the particularities of its own service,
such as the prevalence of HCV and HIV, the demand for blood
components for transfusion and the daily number of samples to be
analyzed. Within these parameters, we developed this method in
consonance to a routine of 50-200 donations/day and a maximum
turnaround time of 12 hours. From March 1998 until July 2005 there
was no single day that we were unable to release NAT results for any
reason. Occasionally, NAT had to be repeated from the beginning, due
to a complete failure of the process, and on one occasion, a strong
contamination required extreme cleaning measures and delayed for
additional eight hours the release of blood components, solved by use
of alternative primers, which are part of our salve guard system. In
general, the rate of repetitions for inadequacy (0.80%) or false-reactivity
(0.16%) is similar to commercial NAT systems currently approved by
regulatory agencies and in use worldwide. In Japan, using a Roche
multiplex real-time PCR system, 0.17% of false-positive results were
observed and 1.99% of the pools demanded repetition of the process
due to internal control failure24. In Europe the combination of NucliSens
extraction (Organon Teknika, Boxtel, Netherlands) and AmpliScreen
(Roche Diagnostic Systems, Branchburg, NJ, USA) is adopted in some
countries like the Netherlands. They reported a rate of 1.01% of invalid
test results and 0.14% of initial false-positives15. The performance of
commercial tests is variable. The rate of invalid runs for the Chiron
TMA assay is 0.1 - 4% and for Roche Ampliscreen 0.1-1.6% while the
Table 7A
ALT values according to Blot and NAT results for anti-HCV reactive




BLOT IND. /NAT NRT (n = 14) 21 9.1 21
BLOT RT/NAT RT (n = 26) 91 77.1 54
BLOT RT/NAT NRT (n = 9) 23 9.1 22
BLOT NRT/NAT NRT (n = 40) 31 19.7 28
Table 7B
Absorbance/Cut-off rate according to Blot and NAT results for anti-HCV
reactive donors (n = 89)
 
Pattern                                                 Absorbance/cut-off rate (EIA)
Mean Standard Median
(A/CO) deviation
BLOT IND. /NAT NRT (n = 14) 1.88 1.07 1.41
BLOT RT/NAT RT (n = 26) 4.63 0.9 4.9
BLOT RT/NAT NRT (n = 9) 4.17 1.4 4.45
BLOT NRT/NAT NRT (n = 40) 1.66 0.85 1.38
1-19, Pools of blood donations. Two positive samples generating three positive “pools” (10, 11 and 16,
arrows). The 308 bp fragment corresponds to amplification of a segment from the external control. The 268
bp band derives from the HCV 5’UTR region. MW = Molecular weight marker, 100 bp ladder (Invitrogen,
São Paulo, Brazil).
Fig. 4 - Routine NAT screening, containing 84 donations, combined into 19 “pools” (1-19).
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specificity lies in between 99.6 - 99.9% for both assays, as reported in
a NAT International Forum5.
The total number of screened samples here presented (139,678)
may be found of low significance when compared to the expected yield
of NAT isolated reactive donations (≥ 1:200,000). Nevertheless, this is
one of the largest series from Brazil presented so far, and the only one
that depicts simultaneous results (screening serology/NAT). Since no
withdrawal of serological screening was implemented, evaluating NAT
and serology on a routine basis also provides a constant challenge and
quality control of both laboratories, and has increased our confidence
in the NAT “in-house” method.
It should be emphasized that the option for an “in-house” system
is not based on economical grounds. Though it would be naive to deny
this aspect as one of the parameters for developing our own method,
several blood banks from wealthy nations (USA6, Japan14, Germany29
and Scotland4) used and some still use such “in-house” systems.
As Brazilian plasma has been sent abroad in exchange for
hemoderivatives, NAT data on Brazilian plasma became available23;
four cases of HCV NAT reactive donations were found among 1,159,241
donations tested (1:289,810). Such NAT reactive samples may be
classified as actually window-period donations only after disclosing
which brand and version of antibody assay was used to screen these
donations (supposedly EIA non-reactive) and documented
seroconversion of implied donors.
Due to the unknown percentage of repeat donors in this series,
estimating the interdonation interval was not attempted, and
consequently, the incidence/window-period model32 cannot be applied.
In this situation, HIV incidence and the transfusional risk may be
estimated by using a modification of the ELISA test called “detuned
assay”17 but for HCV a similar assay has not been described, so, in
practice, risk has to be derived by performing NAT mini-pool testing10.
The 5’-Untranslated Region is the most conserved genomic segment
among HCV isolates. However, some variability can be found inside the
5’UTR affecting the primer binding for some isolates, and thus the
amplification yield. We have tested several published primer combinations
and a new sense primer, based on the comparison of the 5’UTR of several
HCV isolates from all genotypes33. SMITH et al. (1995) has proposed two
20mers showing 100% nucleotide conservancy to all isolates studied, as
theoretically ideal primers33. We have investigated one of these in
combination to HC1831 as the reverse primer. Due to the contamination
problem and time constraints we discarded the performance of “nested-
PCR” and evaluated several primer pairs but always in one round reactions,
taking 2-3 hours to complete. We tested also primer combinations that
would allow the co-amplification of HCV and the control RNA without
significant loss of sensitivity, in a multiplex format.
Sensitivity of the here described method is of 1,000 copies of HCV-
RNA/mL (100% hit rate) and was estimated by testing CLB Pelipsy
standard (Amsterdam, Netherlands) and samples quantified by the
Roche HCV Monitor v1.0 (Roche, Brazil) individually and on pools.
This means that the method is able, on minipools of 8-12, to detect a
positive donor if serum contains > 6,000 copies/mL. After international
standardization of HCV in International Units, and availability of
working reagents to be used as calibrators, we challenged our method
against NISBC HCV international standard, achieving a sensitivity of
500 IU/mL which is in agreement to the units/copies relationship16
(1U ≅ 1-3 copies). The sensitivity achieved, of 500 IU/mL for HCV is
in consonance to the requirements of strict regulatory agencies such
the FDA8 and the Paul-Ehrlich Institute27. In fact, these agencies
stipulate a hit rate of 95% or higher for a donation containing at least
5,000 IU/mL, independently of the pool size. Enhancement of the
sensitivity or processing of larger pool sizes can be achieved by
concentration steps prior to RNA extraction, which we found
unnecessary for the donation volume processed daily in our laboratory.
Seropositive (anti-HCV) donors also NAT-reactive have a trend to
harbor high viral titers, median is > 500,000 copies/mL and only one
sample depicted a titer (26,586 copies/mL) close to the cut-off but was
readily detected by our PCR test19. Viremia in the window period starts
at the day of the inoculum and rapidly increases due to the rapid
doubling time of HCV, estimated as 10.8 hours11. Actually, viral load
presented by NAT-only reactive donors crosses the detection threshold
of NAT-minipool systems a few days after infection. This is illustrated
by viral load determination on a series of 176 NAT HCV reactive donors
detected in the US where only eight displayed a viral load inferior to
5,000 IU/mL (Dr Susan L Stramer, American Red Cross, Gaithersburg,
Maryland, USA, personal communication). This situation of very low
viremia occurs in the period called pre-ramp phase and is responsible
for the still existing transfusional risk for NAT screened blood2.
Unfortunately, it has been proved that even those donations with very
low viremia transmit HCV to receptors at a very high rate25.
Genotypes observed on this donor population follow the pattern
described for HCV patients from the same geographic region3; 73%
genotype 1 (1a and 1b equally frequent), 24% genotype 3 (all 3a) and
3% genotype 2 (all 2b).
Among the PCR-HCV non-reactive donations there were HIV-RNA,
HGV-RNA20 and HBV-DNA positive donors (data not shown), attesting
the high specificity of the method (99.83%). Five donations presented
an amplification product suggestive of HCV in both pools and
subsequently, in individual reactions. However, the confirmatory nested-
PCR was unable to corroborate that, since no amplification was
observed. Sequencing of these amplicons (268 bp, NAT screening)
depicted the presence of HGV sequences in four of them and authentic
HCV in one. We interpreted this finding as PCR false-positives caused
by the undesired capacity of the HCV primers to anneal to HGV
genome. Unexpectedly, this spurious hybridization occurs at the NS3
gene, not at the HGV 5’UTR, where higher homology between both
Flaviviruses do occur. Since these false-positives were only observed
during the months of April and May of 2000, we speculate that a
particular HGV strain was circulating at that time. Another possible
explanation is that one of the reagents (primers, Taq polymerase etc.)
may have presented some performance variability, causing a decrease
in the reaction stringency, which we were unable neither to detect during
quality assurance regular procedures nor to attribute to a particular
component of the amplification mixture. The remaining false-positive
may be ascribed to amplicon carry-over.
The frequency of truly inhibitory samples was very low, only one
sample prevented the amplification of the external control on both
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“pools” and also individually. The donor was asked to return and a
new sample didn’t show inhibition so the donor was re-integrated while
the inhibitory donation was discarded.
We observed 46 donors with a positive EIA and IB and a negative
PCR result both on “pools” and individually (Table 6). We believe that
these persons (46/268 = 17.16%) without detectable viremia (HCV-
RNA) represent cases of previous exposure to HCV with further
clearance of the virus or intermittent viremia. We noticed that ALT
levels are significantly lower on this than on the PCR reactive group
(Table 7a), indicating normal liver function, which is compatible to
absence of hepatic viral replication. On the other hand, the anti-HCV
absorbance/cut-off rate doesn’t differ between the two groups (Table
7b). Moreover, their index sample and follow-up samples were negative
on a more sensitive NAT assay (nested-PCR, sensitivity 100 IU/mL,
99% hit rate). Prospective testing of German blood donors for HCV by
PCR29 has identified a rate of truly positive non-viremic donors of 13/
77 (27%), similar to the one reported here. It is well established that
truly antibody reactive-RNA negative persons correspond to 15-25%
of all HCV infected individuals13.
In conclusion, it was shown that a reliable “in-house” method was
developed and successfully implemented as a routine for several
Brazilian blood banks. So far, the yield of isolated NAT reactive samples
is zero, probably because of the still relatively small number of donors
tested. In fact, in the largest series published35, 170 HCV NAT-reactive/
anti-HCV non-reactive units were identified among 39,721,404 tested,
giving a rate of 1:230,000.
The system in place is an alternative to more expensive commercial
assays; is flexible and allows the fast introduction of new RNA targets,
as shown for HGV20.
 RESUMO
Triagem primária de doadores de sangue por teste de ácidos
nucléicos: desenvolvimento de um método não-comercial e
resultados
Desenvolveu-se uma metodologia própria (“in-house”) baseada em
RT-PCR, que permite detectar simultaneamente o RNA do vírus HCV
e de um RNA artificial empregado como controle externo. As amostras
são analisadas em pools de 6-12 doações, cada doação sendo incluída
em dois pools diferentes, um horizontal e um vertical, permitindo a
identificação imediata de uma doação reativa, sem a necessidade de
desmembrar-se um pool reativo. O processo todo consumiu de 6-8
horas diárias e os resultados foram emitidos em paralelo à sorologia.
O método detectou os seis genótipos de HCV, com um limite de
sensibilidade de 500 UI/mL (95% hit rate). Até julho de 2005 haviam
sido testadas 139.678 doações com a detecção de 315 (0,23%) doações
reativas para HCV-RNA. Exceto cinco falso-positivas, todas estas
doações também apresentavam o respectivo anticorpo, portanto não se
detectou nenhuma doação em janela imunológica. A especificidade
foi de 99,83%. A detecção de amostra em janela imunológica, nesta
população de doadores, provavelmente demandará a análise de um
número maior de doações, espelhando-se na experiência internacional
que tem mostrado a detecção de amostras HCV-RNA isoladas em
1:200.000 - 1:500.000 doações.
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